Generic Rubraca Availability

Last updated on Jun 11, 2025.

Rubraca is a brand name of rucaparib, approved by the FDA in the following formulation(s):

RUBRACA (rucaparib camsylate - tablet;oral)

• Manufacturer: PHARMAAND
  Approval date: December 19, 2016
  Strength(s): EQ 200MG BASE ^[RLD], EQ 300MG BASE ^[RLD]
• Manufacturer: PHARMAAND
  Approval date: May 1, 2017
  Strength(s): EQ 250MG BASE ^[RLD]

Is there a generic version of Rubraca available?

No. There is currently no therapeutically equivalent version of Rubraca available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rubraca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• High dosage strength tablets of rucaparib
  Patent 10,130,636
  Issued: November 20, 2018
  Inventor(s): Etter Jeffrey
  Assignee(s): Clovis Oncology, Inc.
  

  A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.

  Patent expiration dates:

  • August 17, 2035
    
    ✓ 
    Patent use: A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 17, 2035
    
    ✓ 
    Patent use: MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
  • August 17, 2035
    
    ✓ 
    Patent use: A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 17, 2035
    
    ✓ 
    Patent use: A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
• Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
  Patent 10,278,974
  Issued: May 7, 2019
  Inventor(s): Basford Patricia Ann & Campeta Anthony Michael & Gillmore Adam & Jones Matthew Cameron & Kougoulos Eleftherios & Luthra Suman & Walton Robert
  Assignee(s): Pfizer Inc.
  

  The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

  Patent expiration dates:

  • February 10, 2031
    
    ✓ 
    Drug product
• DNA damage repair inhibitors for the treatment of cancer
  Patent 8,071,579
  Issued: December 6, 2011
  Inventor(s): Ashworth; Alan et al.
  Assignee(s): The Institute of Cancer Research: Royal Cancer Hospital (London, GB); Kudos Pharmaceuticals Limited (Cambridge, GB)
  

  The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

  Patent expiration dates:

  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
• DNA damage repair inhibitors for treatment of cancer
  Patent 8,143,241
  Issued: March 27, 2012
  Inventor(s): Ashworth; Alan et al.
  Assignee(s): Kudos Pharmaceuticals Limited (Cambridge, GB); The Institute of Cancer Research (London, GB)
  

  The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

  Patent expiration dates:

  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 12, 2027
    
    ✓ 
    Patent use: A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
• Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
  Patent 8,754,072
  Issued: June 17, 2014
  Inventor(s): Basford Patricia Ann & Campeta Anthony Michael & Gillmore Adam & Jones Matthew Cameron & Kougoulos Eleftherios & Luthra Suman & Walton Robert
  Assignee(s): Pfizer Inc.
  

  The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

  Patent expiration dates:

  • February 10, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
  Patent 8,859,562
  Issued: October 14, 2014
  Inventor(s): Helleday Thomas
  Assignee(s): The University of Sheffield
  

  The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

  Patent expiration dates:

  • August 4, 2031
    
    ✓ 
    Patent use: A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 4, 2031
    
    ✓ 
    Patent use: A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • August 4, 2031
    
    ✓ 
    Patent use: A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
• Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
  Patent 9,045,487
  Issued: June 2, 2015
  Inventor(s): Basford Patricia Ann & Campeta Anthony Michael & Gillmore Adam & Jones Matthew Cameron & Kougoulos Eleftherios & Luthra Suman & Walton Robert
  Assignee(s): PFIZER INC.
  

  The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

  Patent expiration dates:

  • February 10, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
  Patent 9,861,638
  Issued: January 9, 2018
  Inventor(s): Basford Patricia Ann & Campeta Anthony Michael & Gillmore Adam & Jones Matthew Cameron & Kougoulos Eleftherios & Luthra Suman & Walton Robert
  Assignee(s): PFIZER INC.
  

  The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

  Patent expiration dates:

  • February 10, 2031
    
    ✓ 
    Patent use: A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
  • February 10, 2031
    
    ✓ 
    Patent use: A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
• High dosage strength tablets of rucaparib
  Patent 9,987,285
  Issued: June 5, 2018
  Inventor(s): Etter Jeffrey
  Assignee(s): CLOVIS ONCOLOGY, INC.
  

  A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed.

  Patent expiration dates:

  • August 17, 2035
    
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 6, 2025 - FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer